Rogers-Lowell Area News

Highlands Oncology Participation in Clinical Trial Advances Care Worldwide

The research department at Highlands Oncology Group (Highlands) of Rogers and Fayetteville was part of a clinical trial that has led to a new FDA approved drug called Kisqali. Highlands Research department has grown drastically over the years. They now have over 21 research employees and are currently participating in thirty-three clinical trials.

Novartis Kisqali is “now the first and only CDk4/6 inhibitor indicated in the US as first line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women”.

This new approved form of therapy will help women with HR+/Her-2 advanced stage breast cancer “live longer without progression of disease,” said Liz Barrett in a Press Release from Novartis.

“Highlands Oncology Group is proud to help develop new therapies for patients with metastatic breast cancer,” said Dr. J. Thaddeus Beck, Oncologist and Medical Director of Research at HOG. The Highlands research team is motivated to see their work in NWA impact people across the world.

Highlands Oncology Group provides comprehensive cancer care to Northwest Arkansas and the surrounding areas. They focus on offering and providing access to all the resources you might need when faced with a cancer diagnosis. Highlands prides itself on making world renowned cancer care available to patients in Northwest Arkansas so they are able to receive the care and treatment they need close to the ones they love in the place they call home.